After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
LXRX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Lexicon Pharmaceuticals Inc is $401.37M. A total of 3.71 million shares were traded on the day, compared to an average of 4.81M shares.
In the most recent transaction, COATS LONNEL bought 90,000 shares of LXRX for 1.05 per share on Nov 16 ’23. After the transaction, the Chief Executive Officer now owns 914,359 company shares. In a previous transaction on Nov 10 ’23, COATS LONNEL bought 10,000 shares at 1.01 per share. LXRX shares that Chief Executive Officer owns now total 824,359.
Among the insiders who bought shares, DEBBANE RAYMOND acquired of 148,820 shares on Oct 12 ’23 at a per-share price of $1.03. This resulted in the Director holding 1,340,847 shares of LXRX after the transaction. In another insider transaction, DEBBANE RAYMOND bought 342,874 shares at $1.08 per share on Oct 11 ’23. Company shares held by the Director now total 1,192,027.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, LXRX has a high of $3.79 and a low of $0.92.
As of this writing, LXRX has an earnings estimate of $Recursion Pharmaceuticals, Inc. per share for the current quarter. EPS was calculated based on a consensus of Lexicon Pharmaceuticals, Inc. estimates, with a high estimate of $Lantronix, Inc. per share and a lower estimate of $Xerox Holdings Corporation.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. LXRX’s latest balance sheet shows that the firm has $86.74M in Cash & Short Term Investments as of fiscal 2021. There were $2.28M in debt and $22.12M in liabilities at the time. Its Book Value Per Share was $0.38, while its Total Shareholder’s Equity was $113.59M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LXRX is Buy with a score of 4.00.
